While Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has gained 54.95% year-to-date, analysts continue to see 112.80% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy.
A scientist holding a vial of the cancer-fighting drug developed by the biotechnology company.
Two meaningful pipeline and regulatory developments arrived within days of each other, adding fresh momentum to Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s expanding TIL therapy platform.
On June 03, 2026, Australia’s Therapeutic Goods Administration granted approval with conditions for Amtagvi (lifileucel) in previously treated advanced melanoma, making it the third marketing authorization for the therapy. The approval covers adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, if positive for a BRAF V600 mutation, a BRAF inhibitor with or without a MEK inhibitor. The TGA based its decision on safety and efficacy results from the global, multicenter C-144-01 trial. Australia carries the highest rate of melanoma globally, with an estimated 17,000 new cases diagnosed each year and more than 1,500 deaths annually. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) said it is in the process of authorizing its first Australian treatment center.
That followed an earlier pipeline update.
On June 01, 2026, the FDA granted an allowance to proceed with an investigational new drug application for IOV-5001, a next-generation IL-12-tethered TIL therapy. A Phase 1/2 basket trial is set to begin enrolling in the second half of 2026, targeting advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, along with other solid tumors representing more than 100,000 U.S. deaths annually. IOV-5001 is engineered to express IL-12 only within the tumor and tether it to the cell surface to prevent release into the bloodstream, building on an earlier secreted IL-12 TIL therapy that showed a 63% confirmed objective response rate.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company pioneering tumor-infiltrating lymphocyte (TIL) therapies to treat cancer. By harvesting and multiplying a patient’s own immune cells, they create personalized immunotherapies designed to recognize and destroy solid tumors.
While we acknowledge the risk and potential of IOVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IOVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center